AIM: High rates of stent @entity715 (ST) have been reported in @entity1 with out-of-hospital @entity1167 (OHCA) who require a primary percutaneous coronary intervention (PCI). The aim of this study was to assess risk factors of ST in this population with a special focus on antiplatelet therapy administered during the acute phase. MATERIALS AND METHODS: We conducted a retrospective observational study in @entity1 treated with primary PCI after OHCA between 2011 and 2013 in our center. All consecutive @entity1 were treated with mild @entity2332 and dual antiplatelet therapy after primary angioplasty. RESULTS: A total of 101 consecutive @entity1 were included in the present analysis. Mean age was 61.3  12.7 years and 75% of @entity1 had an initial @entity2224 . All @entity1 received @entity117 before PCI. @entity3075 inhibitors were administered after PCI and included @entity1397 (47.5%), @entity3076 (21.8%) or @entity3077 (29.7%). The survival rate at discharge was 44.5%. We identified 11 cases (10.9%) of definite or probable ST ( @entity1397 (n=2), @entity3076 (n=4) and ticagrelor (n=5)) occurring at a median of 2 days after PCI. No specific predictors were found to be significantly associated with ST. New @entity3075 inhibitors were associated with more ST compared to @entity1397 (17.3% vs. 4.2%; respectively, p=0.05). ST was associated with a decreased left ventricular ejection fraction (p=0.007) and with a trend toward a higher mortality compared to @entity1 without ST (82% vs. 52%, p=0.06). CONCLUSION: The incidence of ST in OHCA survivors is high and associated with poor clinical outcome. The use of new oral @entity3075 inhibitors does not appear to be associated with a reduction in ST compared to @entity1397 .

Stent XXXX after primary percutaneous coronary intervention in comatose survivors of out-of-hospital @entity1167 : Are the new @entity3075 inhibitors really more effective than @entity1397 ?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3076 :: ('MESH:C408153', 'Chemical') :: ['prasugrel'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity3077 :: ('MESH:C503700', 'Chemical') :: ['ticagrelor'] @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation'] @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity3075 :: ('64805', 'Gene') :: ['P2Y12'] @entity2332 :: ('MESH:D007035', 'Disease') :: ['therapeutic hypothermia']
@entity715 :: (MESH:D013927,Disease) :: ['thrombosis']
